Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. - Mardani M; Darazam IA; Moini A; Ebrahimi A; Mirhassani R; Barati S; Shahpari R; Modiri G; Fallah N; Albooyeh S; Neyshaburinezhad N; Karimi-Zarchi M; et al. (Vaccine, 2026)